DDInter1724 DDInter1840
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Sulfamethoxazole {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfamethoxazole {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dasatinib
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Toremifene {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Toremifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Toremifene
Toremifene {u} (Compound) causes {v} (Side Effect) Pulmonary embolism
Pulmonary embolism {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Sulfamethoxazole {u} (Compound) resembles {v} (Compound) Dapsone
Dapsone {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfamethoxazole {u} (Compound) downregulates {v} (Gene) RPS4Y1
RPS4Y1 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfamethoxazole (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Sulfamethoxazole (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib and Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene and Toremifene (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene and Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene and Toremifene (Compound) causes Pulmonary embolism (Side Effect) and Pulmonary embolism (Side Effect) is caused by Trabectedin (Compound)
Sulfamethoxazole (Compound) resembles Dapsone (Compound) and Dapsone (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)